Every treatment that exists today: every medication, every therapy, every breakthrough, started somewhere. It started with a question, a hypothesis, and eventually, a clinical trial.
May 20 is National Clinical Trials Day, a moment to recognize the remarkable system that turns scientific ideas into real-world answers. For the NF community (patients, families, caregivers, and advocates) this day carries particular weight. Because for a condition as complex and variable as neurofibromatosis, clinical trials are not just important. They are essential.
What Is a Clinical Trial, Really?
Clinical trials are research studies that test whether a new treatment, drug, device, or approach is safe and effective in people. They follow a careful, phased process, from early safety testing to large-scale studies that confirm whether something truly works.
They are not a last resort. They are not experimental in a reckless sense. They are the gold standard for evidence, the way medicine proves, rigorously and honestly, what helps and what doesn’t.
For NF, Trials Are How Progress Happens
Neurofibromatosis (NF1, NF2, and schwannomatosis) is considered rare, which means researchers can’t rely on massive patient populations to gather data quickly. Every person who participates in an NF clinical trial represents a meaningful contribution to the collective understanding of the disease.
The approval of selumetinib (Koselugo) for children with NF1 and inoperable plexiform neurofibromas in 2020 was a landmark moment: the first FDA-approved drug specifically for NF1. In 2025, that approval was extended to adults as well. And that same year, mirdametinib (Gomekli) became the first treatment approved for both adults and children with NF1-related plexiform neurofibromas. These milestones didn’t happen overnight. They happened because patients and families said yes to participation, because researchers asked the right questions, and because the process worked.
That is what clinical trials make possible.
Participation Is a Gift to the Future
We understand that joining a clinical trial is not a simple decision. There are logistics, travel, time commitments, uncertainty, and emotional weight involved. Participation is a deeply personal choice, and it isn’t right for everyone at every moment.
But for those who are able to participate, even in a study where they may not see direct personal benefit, the impact extends far beyond themselves. Each data point, each response, each reported experience adds to a growing body of knowledge that will shape how NF is treated for the next generation.
To every patient and family who has ever participated in an NF clinical trial: thank you. You are the reason progress is possible.
Take the Next Step
If you or a loved one has NF and you’re curious about whether a clinical trial might be an option, here are some ways to start:
- Visit clinicaltrials.gov and search for “neurofibromatosis” to see studies currently enrolling.
- Talk to your care team about whether your current situation might make you eligible for a trial.
- Reach out to your NF advocacy organization, as they can often help you navigate what’s available and what to expect.
Clinical trials are how we get from where we are to where we need to be. On National Clinical Trial Day and every day, we are grateful for everyone who makes that journey possible.
Support The Research
Participation is one powerful way to drive progress, but it takes funding to get trials off the ground. If you are not in a position to enroll, consider making a donation to help fund the NF research that changes lives.
Responses